Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Population health model for pharmacist assessment and independent prescribing of statins in an ambulatory care setting.

Haby HE, Alm RA, Corona AR, Hall AC.

J Am Pharm Assoc (2003). 2019 Nov 2. pii: S1544-3191(19)30397-8. doi: 10.1016/j.japh.2019.08.003. [Epub ahead of print]

PMID:
31690511
2.

Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.

Singh R, Almutairi M, Alm RA, Lahiri SD, San Martin M, Chen A, Ambler JE.

J Antimicrob Chemother. 2017 Oct 1;72(10):2796-2803. doi: 10.1093/jac/dkx214.

PMID:
29091195
3.
4.

Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.

Lahiri SD, Bradford PA, Nichols WW, Alm RA.

J Antimicrob Chemother. 2016 Oct;71(10):2848-55. doi: 10.1093/jac/dkw248. Epub 2016 Jul 7.

PMID:
27402011
5.

Multi-center and multi-method evaluation of in vitro activities of ceftaroline against S. aureus.

Koeth LM, Apfalter P, Becker K, Gesu G, Martínez-Martínez L, Lahiri SD, Alm RA, Ambler J, Iaconis J.

Diagn Microbiol Infect Dis. 2016 Aug;85(4):452-8. doi: 10.1016/j.diagmicrobio.2016.05.003. Epub 2016 May 8.

PMID:
27233426
6.

Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.

Lahiri SD, Alm RA.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3183-6. doi: 10.1128/AAC.00047-16. Print 2016 May.

7.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):343-7. doi: 10.1128/AAC.01867-15. Print 2016 Jan.

8.

Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.

Lahiri SD, Alm RA.

J Antimicrob Chemother. 2016 Jan;71(1):34-40. doi: 10.1093/jac/dkv329. Epub 2015 Oct 19.

PMID:
26483514
9.

Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).

Su XH, Wang BX, Le WJ, Liu YR, Wan C, Li S, Alm RA, Mueller JP, Rice PA.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):621-3. doi: 10.1128/AAC.01211-15. Print 2016 Jan.

10.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Hoban DJ, Reiszner E, Lahiri SD, Alm RA, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Dec;59(12):7873-7. doi: 10.1128/AAC.01833-15. Epub 2015 Sep 28.

11.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G, Newman JV.

Sci Rep. 2015 Sep 18;5:14157. doi: 10.1038/srep14157. No abstract available.

12.

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G, Newman JV.

Sci Rep. 2015 Jul 14;5:11827. doi: 10.1038/srep11827. Erratum in: Sci Rep. 2015;5:14157.

13.

Ceftaroline Activity against mecC-Containing Staphylococcus aureus.

Lahiri SD, Alm RA.

J Clin Microbiol. 2015 Sep;53(9):3102-3. doi: 10.1128/JCM.01411-15. Epub 2015 Jul 1. No abstract available.

14.

Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.

Lahiri SD, Kutschke A, McCormack K, Alm RA.

Antimicrob Agents Chemother. 2015 Sep;59(9):5278-87. doi: 10.1128/AAC.00571-15. Epub 2015 Jun 15.

15.

Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.

Lahiri SD, McLaughlin RE, Whiteaker JD, Ambler JE, Alm RA.

J Antimicrob Chemother. 2015 Sep;70(9):2488-98. doi: 10.1093/jac/dkv131. Epub 2015 Jun 4.

PMID:
26045529
16.

Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.

Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K, Tanudra MA, Nash TJ, Thresher J, Johnstone MR, Hajec L, Livchak S, McLaughlin RE, Alm RA.

J Antimicrob Chemother. 2015;70(6):1650-8. doi: 10.1093/jac/dkv004. Epub 2015 Feb 1.

PMID:
25645206
17.

Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.

Alm RA, Johnstone MR, Lahiri SD.

J Antimicrob Chemother. 2015 May;70(5):1420-8. doi: 10.1093/jac/dku568. Epub 2015 Jan 28.

PMID:
25634992
18.

Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.

Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, Lewis LA, Su X, Huband MD, Gardner H, Mueller JP.

Antimicrob Agents Chemother. 2015 Mar;59(3):1478-86. doi: 10.1128/AAC.04456-14. Epub 2014 Dec 22.

19.

Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48.

Lahiri SD, Mangani S, Jahić H, Benvenuti M, Durand-Reville TF, De Luca F, Ehmann DE, Rossolini GM, Alm RA, Docquier JD.

ACS Chem Biol. 2015 Feb 20;10(2):591-600. doi: 10.1021/cb500703p. Epub 2014 Dec 4.

PMID:
25406838
20.

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP.

Antimicrob Agents Chemother. 2015 Jan;59(1):467-74. doi: 10.1128/AAC.04124-14. Epub 2014 Nov 10.

21.

The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility.

Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H.

Antimicrob Agents Chemother. 2015 Jan;59(1):427-36. doi: 10.1128/AAC.03954-14. Epub 2014 Nov 3.

22.

Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA.

Antimicrob Agents Chemother. 2014 Oct;58(10):5704-13. doi: 10.1128/AAC.03057-14. Epub 2014 Jul 14.

23.

Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme.

Lahiri SD, Giacobbe RA, Johnstone MR, Alm RA.

J Antimicrob Chemother. 2014 Nov;69(11):2942-6. doi: 10.1093/jac/dku237. Epub 2014 Jun 30.

PMID:
24986496
24.

High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.

Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J, Jensen JS, Ohnishi M, Unemo M.

Antimicrob Agents Chemother. 2014 Sep;58(9):5585-8. doi: 10.1128/AAC.03090-14. Epub 2014 Jun 30.

25.

Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.

Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD.

J Antimicrob Chemother. 2014 Aug;69(8):2065-75. doi: 10.1093/jac/dku114. Epub 2014 Apr 28.

PMID:
24777906
26.

Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk.

Koeth LM, Matuschek E, Kahlmeter G, Alm RA, Ambler JE.

Eur J Clin Microbiol Infect Dis. 2014 Sep;33(9):1511-7. doi: 10.1007/s10096-014-2089-8. Epub 2014 Apr 18.

PMID:
24744220
27.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.

Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL.

J Med Chem. 2012 Aug 9;55(15):6916-33. doi: 10.1021/jm300690s. Epub 2012 Jul 20.

PMID:
22779424
28.

The Genome.

Alm RA, Noonan B.

In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington (DC): ASM Press; 2001. Chapter 27.

29.

UafB is a serine-rich repeat adhesin of Staphylococcus saprophyticus that mediates binding to fibronectin, fibrinogen and human uroepithelial cells.

King NP, Beatson SA, Totsika M, Ulett GC, Alm RA, Manning PA, Schembri MA.

Microbiology. 2011 Apr;157(Pt 4):1161-75. doi: 10.1099/mic.0.047639-0. Epub 2011 Jan 20.

PMID:
21252279
30.

Exploitation of structural and regulatory diversity in glutamate racemases.

Lundqvist T, Fisher SL, Kern G, Folmer RH, Xue Y, Newton DT, Keating TA, Alm RA, de Jonge BL.

Nature. 2007 Jun 14;447(7146):817-22.

PMID:
17568739
31.

Characterization of a complex chemosensory signal transduction system which controls twitching motility in Pseudomonas aeruginosa.

Whitchurch CB, Leech AJ, Young MD, Kennedy D, Sargent JL, Bertrand JJ, Semmler AB, Mellick AS, Martin PR, Alm RA, Hobbs M, Beatson SA, Huang B, Nguyen L, Commolli JC, Engel JN, Darzins A, Mattick JS.

Mol Microbiol. 2004 May;52(3):873-93.

32.

Novel intervention strategies for Helicobacter pylori treatment.

Noonan B, Alm RA.

Curr Drug Targets Infect Disord. 2002 Dec;2(4):331-8. Review.

PMID:
12570739
33.

Identification of strain-specific genes located outside the plasticity zone in nine clinical isolates of Helicobacter pylori.

Chanto G, Occhialini A, Gras N, Alm RA, Mégraud F, Marais A.

Microbiology. 2002 Nov;148(Pt 11):3671-80.

PMID:
12427957
34.

DNA sequence and mutational analyses of the pVir plasmid of Campylobacter jejuni 81-176.

Bacon DJ, Alm RA, Hu L, Hickey TE, Ewing CP, Batchelor RA, Trust TJ, Guerry P.

Infect Immun. 2002 Nov;70(11):6242-50.

35.

Helicobacter pylori: today's treatment, and possible future treatment.

Trust TJ, Alm RA, Pappo J.

Eur J Surg Suppl. 2001;(586):82-8. Review.

PMID:
11718532
36.

A phase-variable capsule is involved in virulence of Campylobacter jejuni 81-176.

Bacon DJ, Szymanski CM, Burr DH, Silver RP, Alm RA, Guerry P.

Mol Microbiol. 2001 May;40(3):769-77.

37.

Involvement of a plasmid in virulence of Campylobacter jejuni 81-176.

Bacon DJ, Alm RA, Burr DH, Hu L, Kopecko DJ, Ewing CP, Trust TJ, Guerry P.

Infect Immun. 2000 Aug;68(8):4384-90.

38.

Comparative genomics of Helicobacter pylori: analysis of the outer membrane protein families.

Alm RA, Bina J, Andrews BM, Doig P, Hancock RE, Trust TJ.

Infect Immun. 2000 Jul;68(7):4155-68.

39.

Analysis of the genetic diversity of Helicobacter pylori: the tale of two genomes.

Alm RA, Trust TJ.

J Mol Med (Berl). 1999 Dec;77(12):834-46. Review.

PMID:
10682319
40.

Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro.

Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust TJ, Hancock RE.

Antimicrob Agents Chemother. 2000 Feb;44(2):248-54.

41.

Helicobacter pylori physiology predicted from genomic comparison of two strains.

Doig P, de Jonge BL, Alm RA, Brown ED, Uria-Nickelsen M, Noonan B, Mills SD, Tummino P, Carmel G, Guild BC, Moir DT, Vovis GF, Trust TJ.

Microbiol Mol Biol Rev. 1999 Sep;63(3):675-707. Review.

42.

Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.

Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ.

Nature. 1999 Jan 14;397(6715):176-80. Erratum in: Nature 1999 Feb 25;397(6721):719.

PMID:
9923682
43.

Mutational analysis of the carboxy-terminal phosphorylation site of GLUT-4 in 3T3-L1 adipocytes.

Marsh BJ, Martin S, Melvin DR, Martin LB, Alm RA, Gould GW, James DE.

Am J Physiol. 1998 Sep;275(3):E412-22. doi: 10.1152/ajpendo.1998.275.3.E412.

PMID:
9725807
44.
45.
46.

The molecular genetics of type-4 fimbriae in Pseudomonas aeruginosa--a review.

Mattick JS, Whitchurch CB, Alm RA.

Gene. 1996 Nov 7;179(1):147-55. Review.

PMID:
8955641
47.

Functional expression of heterologous type 4 fimbriae in Pseudomonas aeruginosa.

Watson AA, Mattick JS, Alm RA.

Gene. 1996 Oct 10;175(1-2):143-50.

PMID:
8917091
49.

Supplemental Content

Support Center